Apogee Therapeutics Inc (NASDAQ: APGE) on Tuesday, plunged -9.70% from the previous trading day, before settling in for the closing price of $39.39. Within the past 52 weeks, APGE’s price has moved between $26.20 and $63.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -51.71%. With a float of $36.22 million, this company’s outstanding shares have now reached $45.99 million.
The extent of productivity of a business whose workforce counts for 196 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Apogee Therapeutics Inc (APGE) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Apogee Therapeutics Inc is 37.94%, while institutional ownership is 83.45%. The most recent insider transaction that took place on Apr 02 ’25, was worth 139,801. In this transaction Chief Medical Officer of this company sold 3,860 shares at a rate of $36.22, taking the stock ownership to the 247,173 shares. Before that another transaction happened on Apr 02 ’25, when Company’s Officer proposed sale 9,310 for $35.61, making the entire transaction worth $331,529.
Apogee Therapeutics Inc (APGE) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.24 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -51.71% per share during the next fiscal year.
Apogee Therapeutics Inc (NASDAQ: APGE) Trading Performance Indicators
Apogee Therapeutics Inc (APGE) is currently performing well based on its current performance indicators. A quick ratio of 18.55 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.23, a number that is poised to hit -1.24 in the next quarter and is forecasted to reach -5.79 in one year’s time.
Technical Analysis of Apogee Therapeutics Inc (APGE)
The latest stats from [Apogee Therapeutics Inc, APGE] show that its last 5-days average volume of 0.58 million was inferior to 0.65 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 52.84%. Additionally, its Average True Range was 2.58.
During the past 100 days, Apogee Therapeutics Inc’s (APGE) raw stochastic average was set at 37.94%, which indicates a significant decrease from 43.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 62.47% in the past 14 days, which was lower than the 74.33% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $35.94, while its 200-day Moving Average is $44.80. Now, the first resistance to watch is $38.07. This is followed by the second major resistance level at $40.57. The third major resistance level sits at $41.88. If the price goes on to break the first support level at $34.26, it is likely to go to the next support level at $32.95. Assuming the price breaks the second support level, the third support level stands at $30.45.
Apogee Therapeutics Inc (NASDAQ: APGE) Key Stats
Market capitalization of the company is 2.08 billion based on 44,882K outstanding shares. Right now, sales total 0 K and income totals -182,150 K. The company made 0 K in profit during its latest quarter, and -67,220 K in sales during its previous quarter.
